58557-62-3

Basic information

• Product Name: 2-bromo-7-nitro-9H-fluoren-9-one
• CAS NO: 58557-62-3
• Molecular Formula: C₁₃H₆BrNO₃
• Molecular Weight: 304.0956
• Mol File: 58557-62-3.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 477.2°C at 760 mmHg
• Flash Point: 242.4°C
• Density: 1.759g/cm³
• Vapor Pressure: 2.86E-09mmHg at 25°C
• Refractive Index: 1.718
• CAS DataBase Reference: 2-bromo-7-nitro-9H-fluoren-9-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-7-nitro-9H-fluoren-9-one(58557-62-3)
• EPA Substance Registry System: 2-bromo-7-nitro-9H-fluoren-9-one(58557-62-3)

Safety Data

• Hazardous Substances Data: 58557-62-3(Hazardous Substances Data)

Upstream product

• 3096-52-4 2-nitro-9H-fluoren-9-one 
• 6638-61-5 2-bromo-7-nitro-9H-fluorene 
• 607-57-8 2-nitro-9H-fluorene 
• 53622-33-6 2-bromo-phenanthrene-9,10-dione 
• 486-25-9 9-fluorenone 
• 64-19-7 acetic acid 
• 3096-56-8 2-bromofluoren-9-one 
• 1940-57-4 9H-fluoren-9-yl bromide 

Downstream Products

• 58557-68-9 2-(7-Amino-9-oxo-9H-fluoren-2-ylamino)-benzoic acid 
• 58557-74-7 N-(Bromofluorenon-9-yl-2)-anthranilsaeure 
• 58557-63-4 2-amino-7-bromo-9H-fluoren-9-one 
• 23842-56-0 2-bromo-7-nitro-fluoren-9-one oxime 

Relevant articles and documents

COMPOSITIONS AND METHODS OF MAKING EXPANDED HEMATOPOIETIC STEM CELLS USING DERIVATIVES OF FLUORENE

This invention is directed to, inter alia, compounds, methods, systems, and compositions for the maintenance, enhancement, and expansion of hematopoietic stem cells derived from one or more sources of CD34+ cells. Sources of CD34+ cells include bone marrow, cord blood, mobilized peripheral blood, and non-mobilized peripheral blood. Also provided herein are compounds of Formula I which are useful in maintaining, enhancing, and expanding of hematopoietic stem cells.

Design, synthesis and biological evaluation of 1,4-Diazobicylco[3.2.2]nonane derivatives as α7-Nicotinic acetylcholine receptor PET/CT imaging agents and agonists for Alzheimer's disease

α7-Nicotinic acetylcholine receptor (α7-nAChR) agonists are promising therapeutic drug candidates for treating the cognitive impairment associated with Alzheimer's disease (AD). Thus, a novel class of derivatives of 1,4-diazobicylco[3.2.2]nonane has been synthesized and evaluated as α7-nAChR ligands. Five of them displayed high binding affinity (Ki = 0.001–25 nM). In particular, the Ki of 14 was 0.0069 nM, which is superior to that of the most potent ligand that was previously reported by an order of magnitude. Four of them had high selectivity for α7-nAChRs over α4β2-nAChRs and no significant hERG (human ether-a-go-go-related gene) inhibition. Their agonist activity was also discussed preliminarily. One of the compounds, 15 (Ki = 2.98 ± 1.41 nM), was further radiolabeled with 18F to afford [18F]15 for PET imaging, which exhibited high initial brain uptake (11.60 ± 0.14%ID/g at 15 min post injection), brain/blood value (9.57 at 30 min post injection), specific labeling of α7-nAChRs and fast clearance from the brain. Blocking studies demonstrated that [18F]15 was α7-nAChR selective. In addition, micro-PET/CT imaging in normal rats further indicated that [18F]15 had obvious accumulation in the brain. Therefore, [18F]15 was proved to be a potential PET radiotracer for α7-nAChR imaging.

Ligand compound of alpha7 nicotinic acetylcholine receptor and application of ligand compound

The embodiment of the invention provides a ligand compound of an alpha7 nicotinic acetylcholine receptor, the ligand compound has one of the following general formulas: wherein (1) X and R1 are shown in the description, and R7 is halogen; (2) R2 is hydrogen, and R3 is halogen or amino; or R3 is hydrogen, and R2 is halogen or amino; (3) R6 is hydrogen, and R4 and R5 are synthesized into a compound shown in the description; or R4 is hydrogen, and R5 and R6 are synthesized into a compound shown in the description; R8 is halogen; and (4) Y is nitrogen or carbon, Z is shown in the description, and R9 and R10 are respectively halogens. The provided ligand compound is an excellent ligand compound of the alpha7 nicotinic acetylcholine receptor. After being chemically marked radioactively, the provided ligand compound of the alpha7 nicotinic acetylcholine receptor can serve as a PET photographic developer.